[go: up one dir, main page]

DK0797439T3 - Anvendelse af pramipexol som et neurobeskyttende middel - Google Patents

Anvendelse af pramipexol som et neurobeskyttende middel

Info

Publication number
DK0797439T3
DK0797439T3 DK95942961T DK95942961T DK0797439T3 DK 0797439 T3 DK0797439 T3 DK 0797439T3 DK 95942961 T DK95942961 T DK 95942961T DK 95942961 T DK95942961 T DK 95942961T DK 0797439 T3 DK0797439 T3 DK 0797439T3
Authority
DK
Denmark
Prior art keywords
pramipexole
neuroprotective agent
neuroprotective
agent
provides
Prior art date
Application number
DK95942961T
Other languages
Danish (da)
English (en)
Inventor
Edward Dallas Hall
Voigtlander Philip F Von
Frank A Rohde
Original Assignee
Upjohn Co
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co, Boehringer Ingelheim Kg filed Critical Upjohn Co
Application granted granted Critical
Publication of DK0797439T3 publication Critical patent/DK0797439T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Semiconductor Memories (AREA)
DK95942961T 1994-12-15 1995-12-12 Anvendelse af pramipexol som et neurobeskyttende middel DK0797439T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/357,121 US5650420A (en) 1994-12-15 1994-12-15 Pramipexole as a neuroprotective agent
PCT/US1995/015613 WO1996018395A1 (fr) 1994-12-15 1995-12-12 Utilisation de pramipexole en tant qu'agent neuroprotecteur

Publications (1)

Publication Number Publication Date
DK0797439T3 true DK0797439T3 (da) 2003-08-25

Family

ID=23404382

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95942961T DK0797439T3 (da) 1994-12-15 1995-12-12 Anvendelse af pramipexol som et neurobeskyttende middel

Country Status (16)

Country Link
US (1) US5650420A (fr)
EP (1) EP0797439B1 (fr)
JP (2) JP4796219B2 (fr)
KR (2) KR100420252B1 (fr)
CN (1) CN1177586C (fr)
AT (1) ATE238790T1 (fr)
AU (1) AU712666B2 (fr)
CA (1) CA2207323C (fr)
DE (1) DE69530606T2 (fr)
DK (1) DK0797439T3 (fr)
ES (1) ES2197213T3 (fr)
MX (1) MX9704377A (fr)
NZ (1) NZ298606A (fr)
PT (1) PT797439E (fr)
SI (1) SI0797439T1 (fr)
WO (1) WO1996018395A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156777A (en) * 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
EP1591119A3 (fr) * 1998-05-15 2007-03-28 Pharmacia & Upjohn Company LLC Pramipexole pour le traitement des maladies du système nerveux central, en particulier la maladie de Parkinson
DK1076559T3 (da) * 1998-05-15 2006-01-16 Pharmacia & Upjohn Co Llc Cabergolin og pramipexol til behandling af CNS-sygdomme især Parkinson's sygdom
US6750235B1 (en) 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
WO2002017931A1 (fr) * 2000-09-01 2002-03-07 Xiaomin Wang Utilisation d'un ou de plusieurs extraits de tripterygium wilfordii hook.f pour la preparation de medicaments destines a prevenir et a traiter des troubles du systeme nerveux
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
WO2002069974A1 (fr) * 2001-03-05 2002-09-12 Andrew Holman Administration d'agents restaurateurs de sommeil
FR2825087B1 (fr) * 2001-05-22 2005-01-14 Galderma Res & Dev Analogues de la vitamine d
DE10137453A1 (de) * 2001-08-02 2003-02-20 Boehringer Ingelheim Pharma Pramlpexol als Antikonvulsivum
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
AU2002360600B2 (en) * 2001-12-11 2007-11-29 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
DE10203103A1 (de) * 2002-01-25 2003-08-07 Boehringer Ingelheim Pharma Pramipexol zur Behandlung von HIV Demenz
US20030166696A1 (en) * 2002-01-24 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexole for the treatment of HIV dementia
PE20040134A1 (es) 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
GB0221513D0 (en) * 2002-09-17 2002-10-23 Generics Uk Ltd Novel compounds and processes
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
WO2005070428A1 (fr) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant un inhibiteur de la recapture de neurotransmetteurs monoamine et un agoniste de la dopamine
WO2006012277A2 (fr) * 2004-06-30 2006-02-02 Amr Technology, Inc. Procede biocatalytique de fabrication de pramipexole enrichi enantiomeriquement
UA95993C2 (ru) 2004-08-13 2011-09-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
DE602006009670D1 (de) * 2005-08-15 2009-11-19 Univ Virginia Neurorestauration mit r(+) pramipexol
EP1940398A1 (fr) * 2005-10-18 2008-07-09 Boehringer Ingelheim International GmbH Utilisation de pramipexol pour traiter le syndrome des jambes sans repos (rls) modere a severe
ITMI20060044A1 (it) * 2006-01-13 2007-07-14 Dipharma Spa Sintesi di intermedi pr la preparazione di pramipexolo
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
ES2379117T3 (es) * 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
WO2008052953A1 (fr) * 2006-10-30 2008-05-08 Boehringer Ingelheim International Gmbh Utilisation du pramipexole ou d'un sel de celui-ci pour le traitement de la maladie de parkinson
WO2008074033A1 (fr) * 2006-12-14 2008-06-19 Knopp Neurosciences, Inc. Compositions et procédés d'utilisation de (r)-pramipexole
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (fr) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthèse de benzothiazole diamines substituées et purifiées du point de vue chiral
CN102186350A (zh) * 2008-08-19 2011-09-14 诺普神经科学股份有限公司 使用(r)-普拉克索的组合物与方法
US20110009460A1 (en) * 2009-06-19 2011-01-13 Valentin Gribkoff Compositions and methods for treating amyotrophic lateral sclerosis
WO2013096816A1 (fr) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Synthèse améliorée de composés substitués par amine de 4,5,6,7-tétrahydrobenzothiazole
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
SMT202100119T1 (it) 2013-07-12 2021-05-07 Knopp Biosciences Llc Trattamento dei livelli elevati di eosinofili e/o basofili
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP3038467B1 (fr) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions et méthodes de traitement de troubles des cellules plasmatiques et de troubles prolymphocytaires à cellules b
WO2016194015A2 (fr) 2015-06-04 2016-12-08 Chiarugi Alberto Utilisation de r(+)-pramipexole (dexpramipexole) pour le traitement d'une ischémie focale cérébrale
US10799484B2 (en) 2017-03-27 2020-10-13 Chase Therapeutics Corporation Compositions and methods for treating synucleinopathies
EP4663182A2 (fr) 2018-03-16 2025-12-17 Scent Science International Inc. Agent prophylactique ou thérapeutique pour lésion hypoxique, lésion d'ischémie-reperfusion et inflammation, agent de protection cellulaire pour transplantation et agent de bioconservation
MX2021007652A (es) * 2018-12-27 2021-08-05 Chase Therapeutics Corp Combinaciones y uso de antineurodegenerativos de domperidona.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung

Also Published As

Publication number Publication date
ATE238790T1 (de) 2003-05-15
CN1169677A (zh) 1998-01-07
KR100420252B1 (ko) 2004-04-21
JPH10510809A (ja) 1998-10-20
AU4413496A (en) 1996-07-03
CA2207323C (fr) 2006-10-10
CA2207323A1 (fr) 1996-06-20
EP0797439A1 (fr) 1997-10-01
US5650420A (en) 1997-07-22
EP0797439B1 (fr) 2003-05-02
DE69530606T2 (de) 2004-02-19
JP4796219B2 (ja) 2011-10-19
CN1177586C (zh) 2004-12-01
ES2197213T3 (es) 2004-01-01
PT797439E (pt) 2003-08-29
JP2007217432A (ja) 2007-08-30
MX9704377A (es) 1998-07-31
DE69530606D1 (de) 2003-06-05
KR100451874B1 (ko) 2004-10-08
NZ298606A (en) 2001-02-23
KR20040000443A (ko) 2004-01-03
SI0797439T1 (en) 2003-12-31
AU712666B2 (en) 1999-11-11
WO1996018395A1 (fr) 1996-06-20

Similar Documents

Publication Publication Date Title
DK0797439T3 (da) Anvendelse af pramipexol som et neurobeskyttende middel
FR2663225B1 (fr) Nouvelle utilisation du modafinil.
PT1193270E (pt) Pirrolobenzodiazepinas
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
TR200200068T2 (tr) Nematisital triflüorobütenler
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
NO306930B1 (no) Anvendelse av 2-amino-6-n-propylamino-4,5,6,7- tetrahydrobenzotiazol (Pramipexol) som et antidepressivt middel
DK1073416T3 (da) Anvendelse af NO som anti-inflammatorisk middel
NO954768D0 (no) N-alkyltiopolyaminderivater som radiobeskyttende midler
FR2701741B1 (fr) Joint homocinetique, notamment du type a tripode.
FI912468A0 (fi) Oxidantkaensliga och -okaensliga aromatiska estrar som inhibitorer foer humant neutrofilelastas.
FI910572A7 (fi) Regnmaetare med anordning som paovisar tilltaeppning.
FI923367L (fi) Molekyler med antikroppkombinations- staellen som katalyserar hydrolysreaktioner.
FI911875L (fi) Kirala 2-(fosfonometoxi) propylguaniner som antivirala aemnen.
NO942472D0 (no) Okulært hypotensivt middel
FI913756L (fi) Foerfarande foer framstaellning av formkroppar ur kiselkarbid som innehaoller infiltrerat kisel.
DK0522212T3 (da) Anvendelsen af et middel til tyrosinaseinhibering
UY24915A1 (es) Derivados de benzoxazindiona, aplicación de los mismos y medicamentos que los contienen
DK0848713T3 (da) Pyridiniminyl-1,2-benzisoxazoler og -benzisothiazoler som antipsykotiske midler
ATE295168T1 (de) Zusammensetzung von riluzol und alpha-tocopherol
FI945414A0 (fi) Menetelmä N,N-disubstituoidun aminofenolin valmistamiseksi
FI913755L (fi) Foerfarande foer framstaellning av formkroppar ur kiselkarbid som innehaoller infiltrerat kisel.
FI913757L (fi) Foerfarande foer framstaellning av formkroppar ur kiselkarbid som innehaoller infiltrerat kisel.
FI960599A7 (fi) 2-oksiminometyyli-1-fenyyli-1,3-propaanidionijohdannaiset herbisideinä
ECSP972052A (es) Quinoxalinadionas